| 2.31 -0.03 (-1.28%) | 10-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.13 | 1-year : | 3.42 |
| Resists | First : | 2.68 | Second : | 2.93 |
| Pivot price | 2.5  |
|||
| Supports | First : | 2.28 | Second : | 1.9 |
| MAs | MA(5) : | 2.36 |
MA(20) : | 2.55 |
| MA(100) : | 2.44  |
MA(250) : | 1.73 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 6.8 |
D(3) : | 5.9 |
| RSI | RSI(14): 27.4 |
|||
| 52-week | High : | 3.16 | Low : | 0.96 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ BOLD ] has closed above bottom band by 4.5%. Bollinger Bands are 12.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.4 - 2.42 | 2.42 - 2.43 |
| Low: | 2.26 - 2.29 | 2.29 - 2.31 |
| Close: | 2.28 - 2.32 | 2.32 - 2.35 |
Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor of checkpoint kinase 1 (CHK1), is currently in Phase 1/2 clinical trials for patients suffering from oncogene amplified cancers. Additionally, Boundless Bio is advancing BBI-825, another oral inhibitor, this one targeting ribonucleotide reductase (RNR), also in Phase 1/2 clinical development for cancer patients exhibiting resistance gene amplifications. A third initiative, the ecDTx 3 program, is designed to target a kinesin crucial for the cellular segregation mechanism of ecDNA. Incorporated in 2018, the company originally operated as Pretzel Therapeutics, Inc. before adopting the name Boundless Bio, Inc. in July 2019. Its headquarters are situated in San Diego, California.
Sun, 11 Oct 2026
Boundless Bio (BOLD) Edges Lower to $2.53 as Shares Hover Near Range Support - Calendar Spread Trade - https://www.siam.in/
Fri, 14 Aug 2026
Boundless Bio (BOLD): Citadel entities and Ken Griffin report 0.6% ownership - Stock Titan
Fri, 26 Jun 2026
BOLD Forecast — Price Target — Prediction for 2027 - TradingView
Thu, 25 Jun 2026
Are TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders? - PR Newswire
Tue, 23 Jun 2026
Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private Placement - The Manila Times
Tue, 23 Jun 2026
BOLD Stock Is Up 90% — Here's What's Behind The Biggest Rally In Company History - Stocktwits
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 23 (M) |
| Shares Float | 16 (M) |
| Held by Insiders | 12 (%) |
| Held by Institutions | 67.2 (%) |
| Shares Short | 778 (K) |
| Shares Short P.Month | 813 (K) |
| EPS | -2.85 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.94 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -32.8 % |
| Return on Equity (ttm) | -67.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.78 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -56 (M) |
| Levered Free Cash Flow | -31 (M) |
| PE Ratio | -0.82 |
| PEG Ratio | 0 |
| Price to Book value | 0.78 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.95 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|